Dieser Maus Monoklonal Antikörper erkennt spezifisch MS4A1 (Rituximab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7795085
Kurzübersicht für Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper (ABIN7795085)
Target
MS4A1 (Rituximab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Maus
Klonalität
Monoklonal
Konjugat
Dieser MS4A1 (Rituximab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Expressionssystem
Mammalian cells
Verwendungszweck
Rituximab Biosimilar, Endotoxin 0.05 EU/mg
Produktmerkmale
B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues. Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Aufreinigung
Protein A or G affinity column
Reinheit
>95 % by reducing SDS-PAGE
Endotoxin-Niveau
Less than 0.5 EU/mg of protein as determined by LAL method